{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:46:25Z","timestamp":1772120785768,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.exphem.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T21:19:10Z","timestamp":1702156750000},"page":"104135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-2328","authenticated-orcid":false,"given":"Mona A.","family":"Alqazzaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genna M.","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-137X","authenticated-orcid":false,"given":"Victoria","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5912-2991","authenticated-orcid":false,"given":"Raquel A.C.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena M.","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella C.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6966-0877","authenticated-orcid":false,"given":"Sehyun","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3250","authenticated-orcid":false,"given":"Cheryl H.","family":"Arrowsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-9621","authenticated-orcid":false,"given":"Dalia","family":"Barsyte-Lovejoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.exphem.2023.11.009_bib0001","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.exphem.2023.11.009_bib0002","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrd2974","article-title":"Protein methyltransferases as a target class for drug discovery","volume":"8","author":"Copeland","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"7330","key":"10.1016\/j.exphem.2023.11.009_bib0003","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-019-0615-2","article-title":"Engaging chromatin: PRC2 structure meets function","volume":"122","author":"Chammas","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.molcel.2019.07.031","article-title":"Non-core subunits of the PRC2 complex are collectively required for its target-site specificity","volume":"76","author":"H\u00f8jfeldt","year":"2019","journal-title":"Mol Cell"},{"issue":"7265","key":"10.1016\/j.exphem.2023.11.009_bib0006","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature08398","article-title":"Role of the polycomb protein EED in the propagation of repressive histone marks","volume":"461","author":"Margueron","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.exphem.2023.11.009_bib0007","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0008","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.exphem.2023.11.009_bib0009","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2023.11.009_bib0010","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"Sashida","year":"2014","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0011","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0012","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cas.14311","article-title":"Synthetic lethal therapy based on targeting the vulnerability of SWI\/SNF chromatin remodeling complex-deficient cancers","volume":"111","author":"Sasaki","year":"2020","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.exphem.2023.11.009_bib0013","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.exphem.2023.11.009_bib0014","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.exphem.2023.11.009_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.exphem.2023.11.009_bib0016","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.exphem.2023.11.009_bib0017","doi-asserted-by":"crossref","first-page":"e61341","DOI":"10.1371\/journal.pone.0061341","article-title":"EZH2 mutations are related to low blast percentage in bone marrow and \u22127\/del(7q) in de novo acute myeloid leukemia","volume":"8","author":"Wang","year":"2013","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.exphem.2023.11.009_bib0018","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/leu.2017.190","article-title":"Molecular characterization of EZH2 mutant patients with myelodysplastic\/myeloproliferative neoplasms","volume":"31","author":"Rinke","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.exphem.2023.11.009_bib0019","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.exphem.2023.11.009_bib0020","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0021","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41598-021-84708-6","article-title":"Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML","volume":"11","author":"Kempf","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2023.11.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106999","article-title":"Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients","volume":"124","author":"Ball","year":"2023","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.4247","article-title":"Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia","volume":"23","author":"G\u00f6llner","year":"2017","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.exphem.2023.11.009_bib0024","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41379-022-01074-y","article-title":"Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes","volume":"35","author":"Sakhdari","year":"2022","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.exphem.2023.11.009_bib0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.advms.2019.07.002","article-title":"EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients","volume":"64","author":"Mechaal","year":"2019","journal-title":"Adv Med Sci"},{"issue":"6","key":"10.1016\/j.exphem.2023.11.009_bib0026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2013.80","article-title":"Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.11.009_bib0027","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.leukres.2017.10.015","article-title":"Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-methylation in myelodysplastic syndrome","volume":"63","author":"Shirahata-Adachi","year":"2017","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.exphem.2023.11.009_bib0028","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.18632\/oncotarget.385","article-title":"Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height","volume":"2","author":"Tatton-Brown","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2023.11.009_bib0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exphem.2018.10.006","article-title":"Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression","volume":"69","author":"Luciani","year":"2019","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cyto.a.22344","article-title":"The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry","volume":"85","author":"Watson","year":"2014","journal-title":"Cytometry A"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0031","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/acschembio.5b00839","article-title":"A potent, selective, and cell-active inhibitor of human Type I protein arginine methyltransferases","volume":"11","author":"Eram","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"16","key":"10.1016\/j.exphem.2023.11.009_bib0032","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","article-title":"Structure-activity relationship studies for enhancer of zeste Homologue 2 (EZH2) and enhancer of zeste Homologue 1 (EZH1) inhibitors","volume":"59","author":"Yang","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.exphem.2023.11.009_bib0033","first-page":"e620","article-title":"Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors","volume":"8","author":"Wadhwa","year":"2016","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.exphem.2023.11.009_bib0034","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.exphem.2023.11.009_bib0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nchembio.2306","article-title":"The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"43","key":"10.1016\/j.exphem.2023.11.009_bib0036","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"19","key":"10.1016\/j.exphem.2023.11.009_bib0037","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","article-title":"ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments","volume":"26","author":"Lachmann","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.exphem.2023.11.009_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2022.09.006","article-title":"Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors","volume":"27","author":"Shinohara","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0039","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.molcel.2018.03.019","article-title":"Distinct stimulatory mechanisms regulate the catalytic activity of polycomb repressive Complex 2","volume":"70","author":"Lee","year":"2018","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.15099","article-title":"Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes","volume":"184","author":"McGraw","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.exphem.2023.11.009_bib0041","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.exphem.2023.11.009_bib0042","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.exphem.2023.11.009_bib0043","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.exphem.2023.11.009_bib0044","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.exphem.2023.11.009_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0046","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12185-016-2124-x","article-title":"Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies","volume":"105","author":"Sashida","year":"2017","journal-title":"Int J Hematol"},{"issue":"14","key":"10.1016\/j.exphem.2023.11.009_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411378","article-title":"Integrative multi-omics analysis of oncogenic EZH2 mutants: from epigenetic reprogramming to molecular signatures","volume":"24","author":"Aldana","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.exphem.2023.11.009_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2022.194840","article-title":"Chemical biology and pharmacology of histone lysine methylation inhibitors","volume":"1865","author":"Barghout","year":"2022","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"4","key":"10.1016\/j.exphem.2023.11.009_bib0049","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.exphem.2023.11.009_bib0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.exphem.2023.11.009_bib0051","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0052","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13148-021-01052-2","article-title":"Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML\/MDS patients","volume":"13","author":"Stomper","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"1","key":"10.1016\/j.exphem.2023.11.009_bib0053","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13148-021-01011-x","article-title":"Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia","volume":"13","author":"van Dijk","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.exphem.2023.11.009_bib0054","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.exphem.2023.11.009_bib0055","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.celrep.2016.11.032","article-title":"Deletion of the polycomb-group protein EZH2 leads to compromised self-renewal and differentiation defects in human embryonic stem cells","volume":"17","author":"Collinson","year":"2016","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.exphem.2023.11.009_bib0056","doi-asserted-by":"crossref","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","article-title":"Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma","volume":"4","author":"Stafford","year":"2018","journal-title":"Sci Adv"},{"issue":"21","key":"10.1016\/j.exphem.2023.11.009_bib0057","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.exphem.2023.11.009_bib0058","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41589-023-01299-1","article-title":"Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma","volume":"19","author":"Kwok","year":"2023","journal-title":"Nat Chem Biol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23017733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23017733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T01:10:03Z","timestamp":1754010603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X23017733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"alternative-id":["S0301472X23017733"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.11.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.20.567858","asserted-by":"object"}]},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104135"}}